Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Mirror Image who wrote (1615)	1/7/2016 6:33:31 PM
From: phoenix_rising	Respond to of 2026

Albeit 6 of the biggest countries in Europe as far as market potential goes. I hadn't noticed about the changes to previously reported numbers, nice catch.

To: Mirror Image who wrote (1615)	1/9/2016 11:18:54 AM
From: eico20	Read Replies (1) \| Respond to of 2026

great points MI, over 1M per month, 10X current sales is what they need to be credible, seems like it's possible in a year or two, and leads back to company comments like Vitaros will be successful when the RTD is distributed worldwide, the RTD opens up Vitaros to recreational users IMO, and especially if they can get OTC status some day given the low side effect profile. In the meantime I like the new slide on the previous Fis trial with ED results, a little more transparency shows confidence.